202 related articles for article (PubMed ID: 26504074)
1. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses.
Manganaro L; Anastasi E; Porpora MG; Vinci V; Saldari M; Bernardo S; Ballesio L; Sollazzo P; Pecorella I; Recchia N; Stracci F; Panici PB; Angeloni A; Catalano C; Scialpi M
Anticancer Res; 2015 Nov; 35(11):6341-51. PubMed ID: 26504074
[TBL] [Abstract][Full Text] [Related]
2. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
3. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
4. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
[TBL] [Abstract][Full Text] [Related]
5. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
7. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
[TBL] [Abstract][Full Text] [Related]
8. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
[TBL] [Abstract][Full Text] [Related]
9. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion.
Polat M; Senol T; Ozkaya E; Ogurlu Pakay G; Cikman MS; Konukcu B; Ozten MA; Karateke A
Clin Transl Oncol; 2016 May; 18(5):457-63. PubMed ID: 26289552
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
12. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network.
Nassir M; Darb-Esfahani S; Richter R; Chekerov R; Hall C; Muallem MZ; Denkert C; Stamatian F; Fotopoulou C; Sehouli J; Braicu EI
Anticancer Res; 2013 Apr; 33(4):1673-7. PubMed ID: 23564814
[TBL] [Abstract][Full Text] [Related]
13. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Azzam AZ; Hashad DI; Kamel NA
Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
[TBL] [Abstract][Full Text] [Related]
15. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
16. Placental type alkaline phosphatase tissue expression in ovarian serous carcinoma.
Orsaria M; Londero AP; Marzinotto S; Di Loreto C; Marchesoni D; Mariuzzi L
Cancer Biomark; 2016; 17(4):479-486. PubMed ID: 27802199
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
18. Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment.
Shen ZY; Shen AJ; Yang SL; Wu MF
Ultrasound Q; 2019 Mar; 35(1):45-53. PubMed ID: 30672869
[TBL] [Abstract][Full Text] [Related]
19. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
